Dysregulated expression of growth factors and their receptors in the development of prostate cancer

Prostate

Volumn 42, Issue 2, 2000, Pages 150-160

  Djakiew, Daniel ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Growth factors; Prostate cancer; Receptors; Review

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

CARCINOGENESIS; DISEASE ASSOCIATION; HUMAN; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW;

BINDING SITES; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GROWTH SUBSTANCES; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR;

EID: 0033955413     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H     Document Type: Review

References (153)

1. Ho SM, Lee K-F, Lane K. Neoplastic transformation of the prostate. In: Naz RK, editor. Prostate: basic and clinical aspects. New York: CRC Press; 1998. p 73-114.
2. Rajan R, Vanderslice R, Kapur S, Lynch J, Thompson R, Djakiew D. Epidermal growth factor (EGF) promotes the chemo-migration of a human prostate cancer cell line and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. Prostate 1996;28: 1-9.
3. Freeman MR, Paul S, Kaefer M, Ishikawa M, Adam RM, Renshaw AA, Elenius K, Klagsbrun M. Heparin-binding EGF-like growth factor in the human prostate: synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen. J Cell Biochem 1998;68:323-328.
4. Connolly JM, Rose DP. Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line. Prostate 1989;15:177-186.
5. Connolly JM, Rose DP. Production of epidermal growth factor and transforming growth factor-α by the androgen-responsive LNCaP human prostate cancer cell line. Prostate 1990;16:209-218.
6. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor-alpha in the progression of prostatic neoplasms. Clin Cancer Res 1995;1:545-550.
7. Tillotson JK, Rose DP. Density-dependent regulation of epidermal growth factor receptor expression in DU-145 human prostate cancer cells. Prostate 1991;19:53-61.
8. Traish AM, Wotiz HH. Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology 1987;121:1461-1467.
9. Jones HE, Eaton CL, Barrow D, Dutkowski CM, Gee JMW, Griffiths K. Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-alpha and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines. Prostate 1997;30:219-231.
10. Fong C-J, Sherwood ER, Mendelson J, Lee C, Kozlowski JM. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carci4oma cells to tumor necrosis factor-α. Cancer Res 1992;52: 5887-5892.
11. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, Goldstein NI. The biological effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996;19: 419-427.
12. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Uberall F, Klocker H. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 1999;59:227-233.
13. Davies P, Eaton CL. Binding of epidermal growth factor by human normal, hypertrophic and carcinomatous prostate. Prostate 1989;14:123-132.
14. Robertson CN, Robertson KM, Herzberg AJ, Kerns BJ, Dodge RK, Paulson DF. Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissues. Surg Oncol 1994;3:237-242.
15. Turkeri LN, Sakr WA, Wykes SM, Grignon DJ, Pontes JE, Macoska JA. Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, pre-malignant, and malignant prostate tissue: Prostate 1994;225: 199-205.
16. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor-α. Cancer Res 1991;51:2780-2785.
17. Jarrard DF, Blitz BF, Smith RC, Patai BL, Rukstalis DB. Effect of epidermal growth factor on prostate cancer cell line PC-3 growth and invasion. Prostate 1994;24:46-53.
18. Zolfaghari A, Djakiew D. Inhibition of chemomigration of the TSU-pr1 human prostatic carcinoma cell line by inhibition of EGF receptor function. Prostate 1996;28:232-238.
19. Xie H, Turner T, Wang M-H, Sing RK, Siegal GP, Wells A. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metastasis 1995;13:407-419.
20. Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostatic cancer and its biologic effects on prostate cancer cells in vitro. Can J Sci Am 1995;3:21-30.
21. Zhou HE, Wan DS, Zhou J, Miller GJ, von Eschenbach AC. Expression of cerb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinog 1992;5:320-327.
22. Myers RB, Srivastava S, Oelschlager DK, Grizzle WE. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 1994;86:1140-1145.
23. Bostwick DG. c-erbB-2 oncogene expression in prostatic intra-epithelial neoplasia: mounting evidence for a precursor role. J Natl Cancer Inst 1994;86:1108-1110.
24. Ross JS, Sheenan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA, Muraca PJ. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol 1997;28:827-833.
25. Ross JS, Sheenan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA, Rifkin MD, Muraca PJ. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997;79:2162-2170.
26. Marengo SR, Sikes RA, Anezinis P, Chang SM, Chung LW. Metastasis induced by overexpression of p185neu-T after orthotopic injection into a prostatic epithelial cell line (NbE). Mol Carcinog 1997;19:165-175.
27. Qui Y, Ravi L, Kung HJ. Requirements of ErbB2 for signaling by interleukin-6 in prostate carcinoma cells. Nature 1998;393: 83-85.
28. Story MT, Hopp KA, Molter M. Expression of transforming growth factor beta 1 (TGF beta 1), -beta 2, and -beta 3 by cultured human prostate cells. J Cell Physiol 1996;169:97-107.
29. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, Lee C. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta I in human prostate cancer cells. Cancer Res 1996;56:44-48.
30. Barrack ER. TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 1997;31:61-70.
31. Perry KT, Anthony CT, Steiner MS. Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate. Prostate 1997;33:133-140.
32. Perry KT, Anthony CT, Case T, Steiner MS. Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 1997;49:151-155.
33. Guo Y, Jacobs SC, Kyprianou N. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer 1997;16:573-579.
34. Guo Y, Kyprianou N. Restoration of transforming growth factor β signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspace-1-mediated apoptosis. Cancer Res 1999;59:1366-1371.
35. Wilding G. Response of prostate cancer cells to peptide growth factors: transforming growth factor-β. Cancer Surv 1991;11: 147-163.
36. Steiner MS. Transforming growth factor-beta and prostate cancer. World Urol J 1995;13:329-336.
37. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ, Mundy GR. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cell line. Prostate 1994;24:204-211.
38. Barnes J, Anthony CT, Wall N, Steiner MS. Bone morphogenetic protein-6 expression in normal and malignant prostate. World Urol J 1995;13:337-343.
39. Bentley H, Hamdy FC, Hart KA, Seid JM, Williams JL, Johnstone D, Russell RG. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1992;66:1159-1163.
40. Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE, Robson CN. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res 1997;57:4427-4431.
41. Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, Hamdy FC. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 1998;78:1219-1223.
42. Ide H, Katoh M, Sasaki H, Yoshida T, Aoki K, Nawa Y, Osada Y, Sugimura T, Terada M. Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs. Oncogene 1997;14:1377-1382.
43. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, Terada M. Growth regulation of human prostate cancer cells by bone mophogenetic protein-2. Cancer Res 1997;57:5022-5027.
44. Thomas TZ, Wang H, Nicalsen P, O'Bryan MK, Evans LW, Groome NP, Pedersen J, Risbridger GP. Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer. J Clin Endocrinol Metab 1997; 82:3851-3858.
45. Thomas TZ, Chapman SM, Hong W, Gurusingfhe C, Mellor SL, Fletcher R, Pedersen J, Risbridger GP. Inhibins, activins, and follistatins: expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia. Prostate 1998;34:34-43.
46. Furst BA, Zhang Z, Ying S-Y. Expression of activin and activin receptors in a human prostatic carcinoma cell line DU145. Int J Oncol 1995;7:239-243.
47. Ying S-Y, Zhang Z, Huang G. Expression and localization of inhibin/activin subunits and activin receptors in the normal rat prostate. Life Sci 1997;60:397-401.
48. Dalkin AC, Gilrain JT, Bradshaw D, Myers CE. Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells. Endocrinology 1996;137:5230-5235.
49. McPherson SJ, Thomas TZ, Wang H, Gurusinghe CJ, Risbridger GP. Growth inhibitory response to activin A and B by human prostate tumor cell lines, LNCaP and DU145. J Endocrinol 1997;154:535-545.
50. Wang GF, Tilly KI, Tilly JL, Preffer F, Schneyer AL, Crowley WF, Sluss PM. Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP. Endocrinology 1996;137:5476-5483.
51. Wang Q, Tabatabaei S, Planz B, Lin CW, Sluss PM. Identification of an activin-follistatin growth modulatory system in the human prostate: secretion and biological activity in primary cultures of prostatic epithelial cells. J Urol 1999;161:1378-1384.
52. Mydlo JH, Michaeli J, Heston WD, Fair WR. Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma. Prostate 1988;13:241-247.
53. Story MT. Regulation of prostate growth by fibroblast growth factors. World J Urol 1995;13:297-305.
54. Story MT, Hopp KA, Molter M, Meier DA. Characteristics of FGF-receptors expressed by stromal cells and epithelial cells cultured from normal and hyperplastic prostates. Growth Factors 1994;10:269-280.
55. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993;13:4513-4522.
56. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R, Zhang J, Bartsch G, Reissigl A, Radmayr C, Thurnher M, Klocker H. Basic fibroblast growth factor levels in cancer cells and in the sera of patients suffering from proliferative disorders of the prostate. Prostate 1997;31:223-233.
57. Chung LW, Li W, Gleave ME, Hsieh JT, Wu HC, Sikes RA, Zhau HE, Bandyk MG, Logothetis CJ, Rubin JS, von Eschenbach AC. Human prostate cancer model: roles of growth factors and extracellular matrices. J Cell Biochem [Suppl] 1992;16: 99-105.
58. Nakamoto T, Chang CS, Li AK, Chodak GW. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1992; 52:571-577.
59. Pienta KJ, Isaacs WB, Vindivich D, Coffey DS. The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol 1991;145:199-202.
60. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G. Structural characterization of biological functions of fibroblast growth factor. Endocr Rev 1987;8:95-114.
61. Bigler SA, Deering RE, Brawer MK. A quantitative morphometric analysis of the microcirculation in prostate carcinoma. Hum Pathol 1993;24:220-226.
62. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-420.
63. Latil A, Baron JC, Cussenot O, Fournier G, Boccon-Gibod L, Le Duc A, Lidereau R. Oncogene amplifications in early-stage human prostate carcinogenesis. Int J Cancer 1994;59:637-638.
64. Donjacour AA, Thomson AA, Cunha GR. Enlargement of the ampullary gland and seminal vesicle, but not the prostate in int-2/Fgf-3 transgenic mice. Differentiation 1998;62:227-237.
65. Yan G, Fukabori Y, Nikolaropolous S, Wang F, McKeehan WL. Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial cell andromedin. Mol Endocrinol 1992;6: 2123-2128.
66. Lu W, Luo Y, Kan M, McKeehan WL. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 1999;274:12827-12834.
67. Ittman M, Mansukhani A. Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. J Urol 1997; 157:351-356.
68. Leung HY, Mehta P, Gray LB, Collins AT, Robson CN, Neal DE. Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene 1997;28:1115-1120.
69. Thomson AA, Foster BA, Cunha GR. Analysis of growth factor and receptor mRNAs during development of the rat seminal vesicle and prostate. Development 1997;124:2431-2439.
70. McGarvey TW, Stearns ME. Keratinocyte growth factor and receptor mRNA expression in benign and malignant human prostate. Exp Mol Pathol 1995;63:52-62.
71. Cunha GR, Foster BA, Sugimura Y, Hom YK. Keratinocyte growth factor as mediator of mesenchymal-epithelial interactions in the development of androgen target organs. Cell Dev Biol 1996;7:1-8.
72. Igarashi M, Finch PW, Aaronson SA. Characterization of recombinant human FGF-10 reveals functional similarities with KGF (FGF-7). J Biol Chem 1998;273:13230-13235.
73. Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 1997;18:3059-3065.
74. Ghosh AK, Shankar DB, Shackleford GM, Wu K, T'Ang A, Miller GJ, Zheng J, Roy-Burman P. Molecular cloning and characterization of human FGF8 alternative messenger RNA forms. Cell Growth Differ 1996;7:1425-1434.
75. Tanaka A, Miyamoto K, Matsuo H, Yoshida H. Human androgen-induced growth factor in prostate and breast cancer cells: its molecular cloning and growth properties. FEBS Lett 1995; 363:226-230.
76. Schmitt JF, Hearn MT, Risbridger GP. Expression of fibroblast growth factor-8 in adult rat tissues and human prostate carcinoma cells. J Steroid Biochem Mol Biol 1996;57:173-178.
77. Leung HY, Dickson C, Robson CN, Neal DE. Overexpression of fibroblast growth factor-8 in human prostate cancer. Oncogene 1996;12:1833-1835.
78. Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, Kobayashi Y, Yoshida H. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancer and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF8. Cancer Res 1998;58:2053-2056.
79. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF binding proteins in primary cultures of prostatic epithelial cells. J Clin Endocrinol Metab 1991;73:401-407.
80. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate SR. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996;81:3774-3782.
81. Iwamura M, Sluss PM, Casamento JB, Cockett ATK. Insulin-like growth factor-I: action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22:243-252.
82. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke L, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogs of insulin-like growth factor I. Cancer Res 1993;53:1102-1106.
83. Kimura G, Kasuya J, Giannini S, Honda Y, Mohan S, Kawachi M, Akimoto M, Fujita-Yamaguchi Y. Insulin-like growth factor (IGF) system components in human prostatic cancer cell lines: LNCaP, DU-145, and PC-3 cells. Int J Urol 1996;3:39-46.
84. Cohen P, Peehl DM, Baker B, Lui F, Hintz RL, Rosenfeld RG. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1994;79:1410-1415.
85. Barni T, Vannelli BG, Sadri R, Pupilli C, Ghiandi P, Rizzo M, Selli C, Serio M, Fiorelli G. Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: gene expression and its cellular localization. J Clin Endocrinol Metab 1994;78:778-783.
86. Connolly JM, Rose DP. Regulation of DU-145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 1994;24:167-175.
87. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollack M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-566.
88. Cohen P. Serum insulin-like growth factor-I levels and prostate cancer risk-interpreting the evidence. J Natl Cancer Inst 1998; 90:911-915.
89. Wolk A, Mantzoros CS, Andersson S-O, Bergstrom R, Signorello LB, Lagiou P, Adami H-O, Trichopoulos D. Insulin-like growth factor-I levels and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:876-879.
90. Kornfeld S. Structure and function of mannose 6-phosphate/insulin-like growth factor II receptor. Annu Rev Biochem 1992; 61:307-330.
91. 125I-insulin-like growth factor degradation by modulating the IGF-II receptor recycling process. J Biol Chem 1985;260:9435-9442.
92. Birnbaum RS, Ware JL, Plymate SR. Insulin-like growth factor-binding protein-3 expression and secretion by cultures of human prostate epithelial cells and stromal fibroblasts. J Endocrinol 1994;141:535-540.
93. Damon SE, Maddison L, Ware JL, Plymate SR. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinology 1998;139:3456-3464.
94. Cohen P, Peehl D, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993;76:1031-1035.
95. Kanteny H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A. Serum insulin like growth factor binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in human prostate cancer cell lines. J Clin Endocrinol Metab 1993;77:229-233.
96. Ho PJ, Baxter RC. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign hyperplasia. Clin Endocrinol 1997;46:145-154.
97. Cohick WS, Clemmons DR. The insulin-like growth factors. Annu Rev Physiol 1993;55:131-153.
98. Cohen P, Graves HCB, Peehl DM, Kamarei M, Guidice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046-1053.
99. Rajah R, Bhala A, Nunn SE, Peehl DM, Cohen P. 7S nerve growth factor is an insulin-like growth factor-binding protein protease. Endocrinology 1996;137:2676-2682.
100. Cohen P, Peehl DM, Graves HCB, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994;142:407-415.
101. MacGrogan D, Saint-Andre J-P, Dicou E. Expression of nerve growth factor and nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines. J Neurochem 1992;59:1381-1391.
102. Paul AB, Grant ES, Habib FK. The expression and localization of β-nerve growth factor (β-NGF) in benign and malignant human prostate tissue: relationship to neuroendocrine differentiation. Br J Cancer 1992;74:1990-1996.
103. Djakiew D, Delsite R, Pflug B, Wrathall J, Lynch JH, Onoda M. Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res 1991;51:3304-3310.
104. Graham C, Lynch JH, Djakiew D. Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol 1992;147:1444-1447.
105. Delsite R, Djakiew D. Characterization of nerve growth factor precursor protein expression by human prostate stromal cells: a role in selective neurotrophin stimulation of prostate epithelial cell growth. Prostate 1999;41:39-48.
106. NTR in a human prostate epithelial tumor cell line reduces NGF induced cell growth by activation of programmed cell death. Mol Carcinog 1998;23: 106-114.
107. Angelsen A, Sandvik AK, Syversen U, Stridsberg M, Waldum HL. NGF-β, NE-cells and prostatic cancer cell lines. Scand J Urol Nephrol 1998;32:7-13.
108. Dalal R, Djakiew D. Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial cells and stromal cells of the human prostate. Mol Cell Endocrinol 1997;134:15-22.
109. Pflug BR, Onoda M, Lynch JH, Djakiew D. Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. Cancer Res 1992; 52:5403-5406.
110. Pflug BR, Dionne CA, Kaplan DR, Lynch JH, Djakiew D. Expression of the Trk high affinity nerve growth factor receptor in the human prostate. Endocrinology 1995;136:262-268.
111. Perez M, Regan T, Pflug B, Lynch J, Djakiew D. Loss of the low affinity nerve growth factor receptor during malignant transformation of the human prostate. Prostate 1997;30:274-279.
112. Djakiew D, Delsite R, Dalal R, Pflug B. The role of the low affinity nerve growth factor receptor and the high affinity Trk receptor in human prostate carcinogenesis. Radiat Oncol Invest 1996;3:333-339.
113. Berg MM, Sternberg DW, Parada LF, Chao MV. K252a inhibits nerve growth factor-induced trk proto-oncogene tyrosine phosphorylation and kinase activity. J Biol Chem 1992;267:13-16.
114. Delsite R, Djakiew D. Anti-proliferation effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines. J Androl 1996;17:481-490.
115. Dionne C, Jani J, Camoratto AM, Emerson E, Neff NT, Vaught J, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs J. Cell-cycle independent death of prostate adenocarcinoma is induced by the Trk tyrosine kinase inhibitor CEP-751. Clin Cancer Res 1998;4:1887-1898.
116. Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 1986;319:743-748.
117. George DJ, Suzuki H, Bova GS, Isaacs JT. Mutational analysis of the TrkA gene in prostate cancer. Prostate 1998;36:172-180.
118. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997;157:2329-2333.
119. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997;157:2323-2338.
120. Guy L, Begin LR, Al-Othman K, Chevalier S, Aprikian AG. Neuroendocrine cells of the verumontanum: a comparative immunohistochemical study. Br J Urol 1998;82:738-743.
121. Campbell CL, Savarese DM, Quesenberry PJ, Savarese TM. Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: predominance of vascular endothelial growth factor. Int J Cancer 1999;15:868-874.
122. Joseph IB, Isaacs JT. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 1997;57:1054-1057.
123. Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ, Dinney CP. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res 1999;5: 783-789.
124. Gridley DS, Andres ML, Slater JM. Enhancement of prostate cancer xenograft growth with whole-body radiation and vascular endothelial growth factor. Anticancer Res 1997;17:923-928.
125. Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998;35:1-10.
126. Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999;161:960-963.
127. Kim HE, Han SJ, Kasaza T, Han R, Choi HS, Palmer KC, Kim HR. Platelet-derived growth factor (PDGF)-signaling mediates radiation-induced apoptosis in human prostate cancer cells with loss of p53 function. Int J Radiat Oncol Biol Phys 1997;39: 731-736.
128. Fudge K, Wang CY, Stearns ME. Immunohistochemical analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostatic adenocarcinomas. Mod Pathol 1994;7:549-554.
129. Vlahos CJ, Kriauciunas TD, Gleason PE, Jones JA, Eble JN, Salvas D, Falcone JF, Hirsch KS. Platelet-derived growth factor induces proliferation of hyperplastic human prostatic stromal cells. J Cell Biochem 1993;52:404-413.
130. Fudge K, Bostwick DG, Stearns ME. Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. Prostate 1996;29:282-286.
131. Seslar SP, Nakamura T, Byers SW. Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors. Cancer Res 1993;53:1233-1238.
132. Kurimoto S, Moriyama N, Horie S, Sakai M, Kameyama S, Akimoto Y, Hirano H, Kawabe K. Co-expression of hepatocyte growth factor and its receptor in human prostate cancer. Histochem J 1998;30:27-32.
133. Humphrey PA, Zhu X, Zarneger R, Swanson PE, Ratliff TL, Volmer RT, Day ML. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147:386-396.
134. Nishimura K, Kitamura M, Takada S, Nonomura N, Tsujimura A, Matsumiya K, Miki T, Matsumoto K, Okuyama A. Regulation of invasive potential of human prostate cancer cell lines by hepatocyte growth factor. Int J Urol 1998;5:276-281.
135. Myers RB, Grizzle WE. Biomarker expression in prostatic intraepithelial neoplasia. Eur Urol 1996;30:153-166.
136. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-298.
137. Degeorges A, Tatoud R, Fauvel-Lafeve F, Podgorniak MP, Millot G, de Cremoux P, Calvo F. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 1996;68:207-214.
138. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995;55:4633-4639.
139. Siegall CB, Scwab G, Nordan RP, Fitzgerald DJ, Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 1990;50:7786-7788.
140. Siegsmund MJ, Yamazaki H, Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol 1994;151:1396-1399.
141. Ritchie CK, Andrews LR, Thomas KG, Tindall DJ, Fitzpatrick LA. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 1997; 138:1145-1150.
142. Mori S, Murakami-Mori K, Bonavida B. Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun 1999;257:609-614.
143. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travalis S, D'Alessandro N. Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibit PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 1999;85:134-144.
144. Stearns M, Wang M, Stearns ME. Cytokine (IL-10, IL-6) induction of tissue inhibitor of metalloproteinase 1 in primary human prostate tumor cell lines. Oncology Res 1995;7:173-181.
145. Wang M, Fudge K, Rhim JS, Stearns ME. Cytokine regulation of the matrix metalloproteinases and their inhibitors in human papillomavirus-18 transformed human prostatic tumor cell lines. Oncol Res 1996;8:303-315.
146. Stearns ME, Rhim JS, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)/MMP-9 secretion. Clin Cancer Res 1999;5:189-196.
147. Akimoto S, Okumura A, Fuse H. Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients. Endocr J 1998;45: 183-189.
148. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182-187.
149. Nakajima Y, DelliPizzi A, Mallouh C, Ferreri NR. Effect of tumor necrosis factor-alpha and interferon-gamma on the growth of human prostate cancer cell lines. Urol Res 1995;23: 205-210.
150. Sherwood ER, Pitt Ford TR, Lee C, Kozlowski JM. Therapeutic efficacy of recombinant tumor necrosis factor alpha in an experimental model of human prostatic carcinoma. J Biol Response Mod 1990;9:44-52.
151. Herrmann JL, Beham AW, Sarkiss M, Chiao PJ, Rands MT, Bruckheimer EM, Brisbay S, McDonnell TJ. Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway. Exp Cell Res 1997;237:101-109.
152. Sensibar JA, Sutkowski DM, Raffo A, Buttyan R, Griswold MD, Sylvester MD, Kozlowski JM, Lee C. Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res 1995;55:2431-2437.
153. Nakajima Y, DelliPizzi A, Mallouh C, Ferreri NR. TNF-mediated cytotoxicity and resistance in human prostate cancer cell lines. Prostate 1996;29:296-302.